SHIP1 inhibition via 3-alpha-amino-cholestane enhances protection against Leishmania infection

Cytokine. 2023 Nov:171:156373. doi: 10.1016/j.cyto.2023.156373. Epub 2023 Sep 28.

Abstract

Leishmania major and L. donovani cause cutaneous leishmaniasis and visceral leishmaniasis, respectively. Available chemotherapies suffer from toxicity, drug-resistance or high cost of production prompting the need for the discovery of new anti-leishmanials. Here, we test a novel aminosteriodal compound- 3-alpha-amino-cholestane [3AC] - that shows selective inhibition of SHIP1, an inositol-5'-phosphate-specific phosphatase with potent effects on the immune system. We report that 3AC-sensitive SHIP1 expression increases in Leishmania-infected macrophages. Treatment of BALB/c mice, a Leishmania-susceptible host, with 3AC increased anti-leishmanial, but reduced pro-leishmanial, cytokines' production and reduced the parasite load in both L. major and L. donovani infections. These findings implicate SHIPi as a potential novel immunostimulant with anti-leishmanial function.

Keywords: 3AC; Leishmania; Macrophages; SHIP1; Th1 response.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Leishmania donovani*
  • Leishmaniasis, Visceral* / drug therapy
  • Mice
  • Mice, Inbred BALB C

Substances

  • 3alpha-aminocholestane
  • Inpp5d protein, mouse